Annales pharmaceutiques francaises最新文献

{"title":"The therapeutic potential of Ribes orientale in hypertension: Improving electrolyte balance, enhancing antioxidant activity, and modulating the muscarinic pathway","authors":"Ambreen Malik Uttra , Suhail Ahmad , Taseer Ahmad , Sumera Qasim , Hafiza Sara Afzal , Waqas Younis","doi":"10.1016/j.pharma.2024.11.004","DOIUrl":"10.1016/j.pharma.2024.11.004","url":null,"abstract":"<div><div>Cardiovascular diseases like hypertension require diuretics, but their effectiveness and side effects limit their use. Alternatives like <em>Ribes orientale</em> extract are being investigated for potential diuretic. In acute diuretic action, the extract and fractions of <em>Ribes orientale</em> were investigated in saline-loaded rats at doses of 12.5, 25, and 50<!--> <!-->mg/kg, p.o., while prolonged diuretic activity was also performed by administration of the most potent and significant dose of <em>Ribes orientale</em> butanol fraction (ROBF) for 7<!--> <!-->days. ROBF diuretic action was confirmed through parameters like urine volume, electrolyte concentration, pH and conductivity. The study found that 50<!--> <!-->mg/kg of ROBF had the most potent and significant diuretic activity, like furosemide (10<!--> <!-->mg/kg). It also produced significant natriuresis and insignificant kaliuresis in electrolyte excretion. ROBF increased diuretic activity significantly from the first and 7th days. In the mechanistic study, it has been evaluated that nitric oxide and prostaglandins pathways are not involved in the diuretic effect of ROBF, while cholinergic pathway might be responsible for the diuretic effect of ROBF. Hematological, renal function tests and histopathological studies confirmed the safety of <em>Ribes orientale</em> at 50<!--> <!-->mg/kg. Results showed slight changes in blood count parameters and no significant changes in creatinine and blood urea nitrogen levels compared to the negative control. Furthermore, downregulation of aldosterone by ROBF prolonged activity enhances the local bradykinin availability that results in marked diuretic and natriuretic activity. It is evident from the decreased level of malondialdehyde (MDA) that <em>Ribes orientale</em> reduces the oxidative stress while increased level of superoxide dismutase (SOD) depicts improving level of antioxidant activity. We conclude that the butanol fraction of <em>Ribes orientale</em> roots possesses a considerable diuretic effect. Therefore, more study is needed to identify the exact mechanism of action and the real efficacy of <em>Ribes orientale</em> as diuretic.</div></div><div><div>Les maladies cardiovasculaires comme l’hypertension nécessitent des diurétiques, mais leur efficacité et leurs effets secondaires limitent leur utilisation. Des alternatives comme l’extrait de Ribes orientale sont à l’étude pour leur potentiel diurétique. En ce qui concerne l’action diurétique aiguë, l’extrait et les fractions de Ribes orientale ont été étudiés chez des rats’ chargés en solution saline à des doses de 12,5, 25 et 50<!--> <!-->mg/kg, p.o., tandis qu’une activité diurétique prolongée a également été réalisée par l’administration de la dose la plus puissante et la plus significative de fraction butanol orientale Ribes (ROBF) pendant 7 jours. L’action diurétique du ROBF a été confirmée par des paramètres tels que le volume d’urine, la concentration d’électrolytes, le pH","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"83 2","pages":"Pages 389-400"},"PeriodicalIF":1.0,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The implications of the EU ban on titanium dioxide: A comprehensive review of safety concerns and alternatives.","authors":"Varsha Pokharkar, Sejal Chandak, Rutika Pawar, Akshay Khandke","doi":"10.1016/j.pharma.2024.11.002","DOIUrl":"10.1016/j.pharma.2024.11.002","url":null,"abstract":"<p><p>Titanium dioxide, a naturally occurring compound, has been extensively utilized across various industries such as food, pharmaceuticals, and cosmetics. In the food sector, it was commonly employed as a color and opacity enhancer under the designation E171. However, due to safety concerns, the EU has prohibited its use as a food additive, effective August 2022, following a six-month transition period. The decision was based on scientific research highlighting risks associated with inhaling titanium dioxide nanoparticles and its potential genotoxic effects. This review also summarizes the implications of this ban on the pharmaceutical industry, where titanium dioxide is utilized in drug manufacturing. While the safety of titanium dioxide in tablets remains inconclusive, the EU's regulatory action has prompted a closer examination of alternative options. While alternatives exist, they may not provide the same benefits as TiO₂, particularly in pharmaceuticals. Further research is needed to determine the safety and effectiveness of TiO₂ and its alternatives in these applications.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of utilization deficiencies post SAP enterprise resource planning implementation in the Algerian Pharmaceutical Sector","authors":"Mariah Khaldi ,&nbsp;Redouane Amine Cherif ,&nbsp;Houssem Belmekki","doi":"10.1016/j.pharma.2024.11.003","DOIUrl":"10.1016/j.pharma.2024.11.003","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;Enterprise Resource Planning like SAP are software solutions integrating various functional aspects. The study investigates the utilization challenges after the adoption of SAP ERP within a pharmaceutical firm. It is driven by four interrelated objectives: comprehending the operation of the SAP, the motivations behind its implementation, identifying the utilization deficiencies, and examining the relation between deficiencies and implementation challenges.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and methods&lt;/h3&gt;&lt;div&gt;A triangulation approach was adopted. The methods employed are based on batch monitoring, data collection, semi-structured interviews, a literature review, an overview of the software package, a comparison of the SAP with the previous management system, and an in-depth implementation study.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Thirty-eight challenges were found in the literature, in a causal relationship with 11 identified utilization deficiencies in the study field. This analysis emphasized the significance of the human dimension, particularly the training of users, as a critical element in SAP implementation.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;The advantages gained from implementing an ERP primarily revolve around the users and the processes. Deployment in itself is not an improvement. By recognizing the importance of the human factor, organizations can focus on improving training programs and enhancing user proficiency to maximize the benefits of SAP implementation.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectif&lt;/h3&gt;&lt;div&gt;Les progiciels de gestion intégrés tels que SAP sont des solutions logicielles qui intègrent divers aspects fonctionnels. L’étude examine les difficultés d’utilisation après l’adoption de SAP ERP au sein d’une entreprise pharmaceutique, et est motivée par quatre objectifs interdépendants: comprendre le fonctionnement de SAP, les motivations derrière sa mise en œuvre, identifier les lacunes d’utilisation, et examiner la relation entre les lacunes d’utilisation et les difficultés de mise en œuvre.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Matériels et méthodes&lt;/h3&gt;&lt;div&gt;Une approche par triangulation méthodologique a été adoptée. Les méthodes employées sont basées sur le suivi des lots, la collecte de données, des entretiens semi-structurés et une revue de la littérature.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résultats&lt;/h3&gt;&lt;div&gt;Une liste de 38 défis a été trouvée dans la littérature, en relation causale avec 11 déficiences d’utilisation identifiées dans le domaine de l’étude. Cette analyse a mis en évidence l’importance de la dimension humaine, en particulier la formation des utilisateurs, en tant qu’élément critique de la mise en œuvre de SAP.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Les avantages d’un ERP concernent principalement les utilisateurs et les processus. Le déploiement en lui-même n’est pas une amélioration. En reconnaissant l’importance du facteur humain, les organisations peuvent se focaliser sur l’amélioration des programmes de formatio","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"83 2","pages":"Pages 378-388"},"PeriodicalIF":1.0,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Montmorillonite: An advanced material with diverse pharmaceutical and medicinal applications.","authors":"Sagar Fatale, Javesh K Patil, Chandrakantsing V Pardeshi, Vishal V Pande, Mangesh A Bhutkar, Komal Parashar, Raju O Sonawane","doi":"10.1016/j.pharma.2024.11.001","DOIUrl":"10.1016/j.pharma.2024.11.001","url":null,"abstract":"<p><p>Montmorillonite (MMT) clay is composed of naturally layered silicate. The clays were more popular in the pharmaceutical and other various fields due to their beneficial physicochemical properties viz. non-toxicity, high surface area, efficient adsorption capability, high swellability, high dispersibility, thixotropic behaviour, and cation exchange capacity. Chemically modified clay provides significant opportunities in variety of applications. MMT finds very crucial place in pharmaceutical field owing to its medicinal properties, which may be used to delay the drug release in chronic physiological conditions and the targeted drug release as well. It is also used to improve the dissolution rate of certain drug molecules, which increased the attention of the researchers to explore the MMT for drug delivery applications. MMT clay has been used as pharmaceutical aids viz. suspending agent, lubricant, anticaking agent, diluent, emulsifier, nanocomposites-forming material, and sometimes filler. MMT clay have been investigated in the fabrication of different pharmaceutical formulations viz. hydrogel, films, nanocomposites, and matrix-based systems. MMT has obtained industrial importance due to its adsorption property and also finds use in wastewater treatment. Other than this, MMT also finds applications in cosmetic industry, food industry, and paper industry. Considering the wide applicability of MMT, it is need of an hour to explore the MMT for further commercial exploitation.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Automated dispensing cabinet: An evaluation of professional practices that says much more than what the authors write].","authors":"Bruno Charpiat","doi":"10.1016/j.pharma.2024.10.011","DOIUrl":"10.1016/j.pharma.2024.10.011","url":null,"abstract":"","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142563413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with therapeutic non-adherence in asthmatic patients: A multicenter study in Algeria","authors":"Akli Islem Chebli ,&nbsp;Zeyneb Chelighem ,&nbsp;Younes Zebbiche ,&nbsp;Sara Abdennour ,&nbsp;Ahmed Amziane ,&nbsp;Reda Djidjik","doi":"10.1016/j.pharma.2024.10.010","DOIUrl":"10.1016/j.pharma.2024.10.010","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Effective medication adherence, is a real global challenge that emerges as a pivotal factor influencing asthma control, exacerbation frequency, hospitalization rates and ultimately, mortality, morbidity and health care costs. In light of this, our study aimed to assess therapeutic adherence levels among asthmatic patients and identify factors contributing to non-adherence.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;We conducted a descriptive, cross-sectional multicenter study, among asthmatic patients receiving outpatient or inpatient care across seven asthma centers located in two Algerian cities: Algiers (University Hospital Center of Benimessous, University Hospital Center of Bab el oued,EPSP of Zeralda, EPSP of Beraki and EPSP of Rouiba) and Constantine (Constantine University Hospital Center (CHU), EPSP of Constantine), between July and December 2023. We evaluated therapeutic adherence using the Morisky 8-item questionnaire, while a 12-item questionnaire assessed patients’ knowledge levels. Logistic regression analysis enabled us to identify factors associated with non-adherence.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Our study, involved 390 patients, with a median age of 34 years and a sex ratio of 1.5. Notably, 38.2% of asthmatic patients exhibited poor adherence to treatment. Multivariate analysis revealed several factors potentially linked to non-adherence, including, age, place of residence, employment status, access to social insurance, treatment type and complexity, auto-medication, occurrence of adverse effects, limited level of education and inadequate knowledge about asthma management. Furthermore, there was a significant correlation between non-adherence and a higher rate of asthma exacerbations, with a reported occurrence of 68%.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Our findings emphasize concerning levels of therapeutic adherence, given its impact on disease control and the quality of life of asthmatic patients. This underscores the importance of implementing a therapeutic education program aimed at improving treatment adherence by addressing the factors identified as barriers in clinical patient management.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;L’observance efficace des médicaments est un véritable défi mondial qui émerge comme un facteur crucial influençant la maîtrise de l’asthme, la fréquence des exacerbations, les taux d’hospitalisation et, finalement, la mortalité, la morbidité et les coûts des soins de santé. À la lumière de cela, notre étude visait à évaluer les niveaux d’observance thérapeutique chez les patients asthmatiques et à identifier les facteurs contribuant à la non-observance.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthodes&lt;/h3&gt;&lt;div&gt;Nous avons mené une étude descriptive, transversale et multicentrique, parmi des patients asthmatiques recevant des soins ambulatoires ou hospitaliers dans sept centres d’asthme situés dans deux villes algériennes : Alger (centre hospitalier universitaire de Benimessous,","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"83 2","pages":"Pages 367-377"},"PeriodicalIF":1.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142563418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced stability-indicating RP-HPLC method for the quantification of lurasidone hydrochloride in bulk and PLGA-based in situ implant formulation","authors":"Bankar Anup Ramprasad ,&nbsp;Sundeep Chaurasia ,&nbsp;Indu Singh","doi":"10.1016/j.pharma.2024.10.008","DOIUrl":"10.1016/j.pharma.2024.10.008","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;The aims of the present investigation was to develop and validate stability-indicating RP-HPLC method for the estimation of Lurasidone hydrochloride (LURA-H) followed by its drug product, LURA-H encapsulated poly-D,L lactic-glycolic acid (PLGA) based in situ depot forming implant (LURA-H-PLGA-ISI).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;The LURA-H-PLGA-ISI formulation was developed by simple mixing method. According to international conference on harmonization guidelines, RP-HPLC method was developed and validated using Waters 2695 and discovery C18, 5μ, 250&lt;!--&gt; &lt;!--&gt;×&lt;!--&gt; &lt;!--&gt;4.6&lt;!--&gt; &lt;!--&gt;mm ID column. Force degradation studied were performed by various degradation techniques.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The chromatographic separations of LURA-H as well as LURA-H-PLGA-ISI with good resolutions have been achieved using the mobile phase 0.1% orthophosphoric acid and acetonitrile (50:50). The linearity in the range of 25–150 μg/mL of developed method. LOD and LOQ limits for LURA-H were found to be 0.07&lt;!--&gt; &lt;!--&gt;μg/mL and 0.22&lt;!--&gt; &lt;!--&gt;μg/mL, respectively. The % RSD was found to be&lt;!--&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;2% showing the precision of developed method. The accuracy of developed method was demonstrated which is close to 100&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;2%. Little modifications in the chromatographic conditions indicated robustness of the developed method. Further, solution stability of LURA-H and LURA-H-PLGA-ISI was stable at room temperature. Furthermore, force degradation studies demonstrated LURA-H was unaffected and stable under thermal, photodegradation and neutral (hydrolytic) stress conditions. AGREE and GAPI assessment demonstrated the developed method is environmentally sustainable.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;The developed method is simple, robust, precise, accurate and sensitive which can be utilized for the regular analysis of LURA-H in quality control laboratories of bulk drug substance and PLGA containing formulations of LURA-H.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectifs&lt;/h3&gt;&lt;div&gt;Les objectifs de cette étude étaient de développer et de valider une méthode CLHP indicatrice de stabilité pour l’estimation du chlorhydrate de lurasidone (LURA-H) et de son produit médicamenteux, l’acide poly-D,L lactique-glycolique encapsulé LURA-H. (PLGA) implant formant dépôt in situ (LURA-H-PLGA-ISI).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthodes&lt;/h3&gt;&lt;div&gt;La formulation LURA-H-PLGA-ISI a été développée par une méthode de mélange simple. Conformément aux directives de la conférence internationale sur l’harmonisation, la méthode CLHP a été développée et validée à l’aide d’une colonne Waters 2695 et Discovery C18, 5&lt;!--&gt; &lt;!--&gt;μ, 250Å∼4,6&lt;!--&gt; &lt;!--&gt;mm ID. La dégradation forcée a été réalisée sous plusieurs conditions stressées.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résultats&lt;/h3&gt;&lt;div&gt;Les séparations chromatographiques de LURA-H ainsi que LURA-H-PLGA-ISI avec de bonnes résolutions ont été réalisées en utilisant la phase mobile 0,1 % d’acide orthophosphorique/acét","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"83 2","pages":"Pages 342-357"},"PeriodicalIF":1.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142563416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-medication of the pediatric population by parents in Morocco: Survey in the Midelt region","authors":"Ghita Meknassi Salime ,&nbsp;Ali Cherif Chefchaouni ,&nbsp;Omar ElHamdaoui ,&nbsp;Yassir Elalaoui","doi":"10.1016/j.pharma.2024.10.009","DOIUrl":"10.1016/j.pharma.2024.10.009","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Self-medication, the practice of administering medications without a medical prescription, has become a ubiquitous reality in many homes. Although often seen as a practical solution to alleviate minor ailments, it also raises major concerns, particularly when it involves children. Indeed, self-medication among children by their parents is a complex phenomenon, influenced by various social, cultural and economic factors.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;The main objective of our study is to evaluate the prevalence of self-medication of the pediatric population by parents in the Midelt region and to identify its determinants.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;A descriptive cross-sectional study was conducted through a questionnaire with 127 parents of children under 12 years old visiting community pharmacies in the region, between May 1 and October 31, 2022.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The prevalence of self-medication was 92.9%, the majority of parents resorted to self-medication of their children for benign pathologies; transient fever, minimal pain and nasopharyngitis. This self-medication is done very early, between 6 months and 2 years. In all, 41.5% of parents used age as a criterion to determine the dose, 49.2% exchanged the dose measurement system between two medications, 76.3% used drug combinations for self-medication, antipyretic analgesics and antibiotics are the therapeutic classes most used in self-medication, 42.2% use the syrup or oral suspension form when self-medicating their children and 64% stated that the pharmacist is their source of information relating to medications.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;This research found widespread use of self-medication among children by their parents, particularly among those with secondary education living in urban area. These findings underline the need to develop a therapeutic education program intended for families, in collaboration with community pharmacists and various health professionals. The aim is to strengthen the safety of children by encouraging more responsible medical practices within homes.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;L’automédication, pratique consistant à administrer des médicaments sans ordonnance médicale, est devenue une réalité omniprésente dans de nombreux foyers. Bien que souvent perçue comme une solution pratique pour soulager les maux mineurs, elle suscite également des préoccupations majeures, en particulier lorsqu’elle concerne les enfants. En effet, l’automédication chez les enfants par leurs parents est un phénomène complexe, influencé par divers facteurs sociaux, culturels et économiques.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectif&lt;/h3&gt;&lt;div&gt;L’objectif principal de notre étude est d’évaluer la prévalence de l’automédication de la population pédiatrique par les parents dans la région de Midelt et d’identifier ses déterminants.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Matériels et méthodes&lt;/h3&gt;&lt;div&gt;Une étude transversale descri","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"83 2","pages":"Pages 358-366"},"PeriodicalIF":1.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142563419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Évaluation de l’impact économique et du parcours patient lors du traitement de l’occlusion coronaire totale chronique","authors":"Lucas Delporte ,&nbsp;Marie-Caroline Brianceau ,&nbsp;Emir Kaïs Rihani ,&nbsp;Morgane Masse ,&nbsp;Claire Lauerière ,&nbsp;Pascal Odou ,&nbsp;Cédric Delhaye ,&nbsp;Bertrand Décaudin","doi":"10.1016/j.pharma.2024.10.006","DOIUrl":"10.1016/j.pharma.2024.10.006","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objectif&lt;/h3&gt;&lt;div&gt;L’occlusion coronaire totale chronique (CTO) est définie par l’absence complète de flux coronaire antérograde sans passage de produit de contraste, datant de plus de 3 mois. La désobstruction de CTO est une procédure d’angioplastie complexe fortement consommatrice de dispositifs médicaux (DM), dont la consommation et le coût ne sont pris en intégralement compte ni dans l’acte médical selon la classification CCAM, ni dans le tarif d’hospitalisation et le financement en sus des DM. L’objectif de l’étude est d’analyser la soutenabilité financière de cette activité pour un établissement public de santé est ainsi d’évaluer l’impact budgétaire du traitement d’une CTO sur les postes de dépenses les plus coûteux. L’objectif secondaire est de décrire le parcours intra-hospitalier du patient.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthodes&lt;/h3&gt;&lt;div&gt;Les séjours pour désobstruction de CTO sont groupés dans la racine de GHM 05K06 « Endoprothèses vasculaires sans infarctus du myocarde ». Les postes de coûts les plus importants ont été identifiés à partir de l’ENC nationale. Leurs montants ont été comparés à ceux de notre étude de coût. Toutes les interventions de CTO de janvier à novembre 2021, ont été récupérées rétrospectivement. Le prix d’achat par l’établissement en 2021 est considéré pour déterminer le coût des dispositifs médicaux. Les données cliniques sont issues du dossier patient informatisé. Les données opératoires (durée de l’intervention, professionnels et DM utilisés) sont extraites. Le coût des ressources humaines (RH) a été intégré aux calculs effectués. Un diagramme de Sankey représentant le parcours patient est réalisé.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résultats&lt;/h3&gt;&lt;div&gt;Dans notre étude, 41 patients ont été inclus pour 45 interventions. L’âge médian était de 65 ans. Soixante-dix-huit pour cent des interventions étaient un succès pour une durée médiane de 113&lt;!--&gt; &lt;!--&gt;minutes. Deux cent deux références différentes de DM étaient utilisées dont 27 % remboursées en sus et 73 % financées par le groupe homogène de séjours (GHS). Le coût total des DM décrit dans l’ENC est de 2142€ dont 721€ sont financés dans le GHS. Dans notre cohorte cela représentait respectivement une moyenne de 2736€&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;1393€ et 1710€&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;926€. Au niveau des RH, le coût total décrit dans l’ENC est de 442€ contre 410&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;169€ dans notre cohorte. Enfin, l’analyse du parcours des patients montre une durée moyenne de séjour (DMS) de 1,8&lt;!--&gt; &lt;!--&gt;jours. Deux parcours sont identifiés dépendant du contexte d’admission, l’hospitalisation de semaine ou les soins intensifs de cardiologie.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;La désobstruction de CTO est une intervention programmée avec une DMS courte et un parcours patient très normalisé. Notre étude souligne une multiplication des références de DM utilisés au cours des désobstruction de CTO par des développements industriels innovants. L’écart des coûts avec l’ENC confirme le beso","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"83 2","pages":"Pages 322-330"},"PeriodicalIF":1.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antioxidant potential and phytochemical constituents of a synergy-based combined extract of Spondias mombin L., Spilanthes filicaulis (Schumach. & Thonn.) C.D.Adams and Piper guineense Thonn","authors":"Konei Emangbondji Hounsou ,&nbsp;Mubo Adeola Sonibare ,&nbsp;Taiwo Olayemi Elufioye","doi":"10.1016/j.pharma.2024.10.007","DOIUrl":"10.1016/j.pharma.2024.10.007","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;Recent advancements in scientific understanding of free radicals have stimulated progress in medicine. Antioxidants are known to neutralize free radicals by giving up electrons. The current research was carried out to explore the antioxidant capabilities and phytochemical composition of a synergy-based combined extracts of &lt;em&gt;Spondias mombin,&lt;/em&gt; &lt;em&gt;Spilanthes filicaulis,&lt;/em&gt; and &lt;em&gt;Piper guineense&lt;/em&gt;, with the goal to determine the optimal ratio for the most effective antioxidant activity, suitable for herbal product development.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Material and methods&lt;/h3&gt;&lt;div&gt;Combined extracts H1 and H2 were obtained through aqueous maceration of &lt;em&gt;S.&lt;/em&gt; &lt;em&gt;mombin&lt;/em&gt; leaves, &lt;em&gt;S.&lt;/em&gt; &lt;em&gt;filicaulis&lt;/em&gt; plants, and &lt;em&gt;P.&lt;/em&gt; &lt;em&gt;guineense&lt;/em&gt; fruits. Antioxidant activity of combined extract was evaluated in 2, 2-diphenyl-1-picrylhydrazyl (DPPH) and ferric ion reducing power (FRAP) assay. Evaluations included total phenolic and flavonoid content determination. Furthermore, the phytochemical constituents were determined using Gas Chromatography-Mass Spectrometry (GC-MS).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The combined extract H1 exhibited better free radical scavenging ability in DPPH (IC&lt;sub&gt;50&lt;/sub&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;72.87&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;0.63&lt;!--&gt; &lt;!--&gt;μg/mL) than H2 (IC&lt;sub&gt;50&lt;/sub&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;150.2&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;1.08&lt;!--&gt; &lt;!--&gt;μg/mL). The FRAP assay results revealed its highest reducing power (12.385&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;0.002 AAE/mg/g) compared to H2 (11.657&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;0.002 AAE/mg/g). Additionally, H1 had higher of both total phenolic and flavonoid content. GC-MS profiling revealed 28 compounds within H1 and 17 compounds within H2.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;This study demonstrated that the combined extract H1 has significant antioxidant potential, with consistently positive results across all conducted assays. It contains a variety of phytochemical constituents, mainly phenolic and flavonoids that could be explored in pharmaceutical industries to develop antioxidant agents.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectif&lt;/h3&gt;&lt;div&gt;Les nouvelles connaissances scientifiques sur les radicaux libres ont stimulé les progrès en médecine. Les antioxydants sont connus pour neutraliser les radicaux libres en cédant des électrons. La présente recherche vise à explorer les capacités antioxydantes et la composition phytochimique d’extraits combinés synergiques de &lt;em&gt;Spondias mombin&lt;/em&gt;, &lt;em&gt;Spilanthes filicaulis&lt;/em&gt; et &lt;em&gt;Piper guineense&lt;/em&gt;, dans le but de déterminer le ratio optimal pour une activité antioxydante maximale, adapté au développement de produits à base de plantes.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Matériels et méthodes&lt;/h3&gt;&lt;div&gt;Les extraits combinés H1 et H2 ont été obtenus par macération aqueuse des feuilles de &lt;em&gt;S.&lt;/em&gt; &lt;em&gt;mombin&lt;/em&gt;, des plantes entières de &lt;em&gt;S.&lt;/em&gt; &lt;em&gt;filicaulis&lt;/em&gt; et des fruits de &lt;em&gt;P.&lt;/em&gt; &lt;em&gt;guineense&lt;/em&gt;. L’activité antioxydante de","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"83 2","pages":"Pages 331-341"},"PeriodicalIF":1.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}